Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Mar
06
Putting People First to Create a More Sustainable Healthcare System
Feb
28
UCB on Growth Path for a Decade Plus
Feb
22
Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases
Feb
12
Harmony in Health: Partnering for Enhanced Seizure Management and Understanding
Jan
11
Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases
Jan
03
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
Dec
02
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
Dec
01
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
Dec
01
Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS
